Patents by Inventor Michael Deligny
Michael Deligny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240400581Abstract: The present disclose includes, among other things, methods of preparing compound (R)-11. or a pharmaceutically acceptable salt thereof. Compound (R)-11 is useful to treat or lessen the severity of cancer.Type: ApplicationFiled: April 2, 2024Publication date: December 5, 2024Applicant: iTeos Belgium SAInventors: Michael Deligny, Eric Talbot, Mustafa Moroglu, Didier Roche, Hugues Lemoine, Xin Huang, Cuicui Yuan, Deju Shang
-
Publication number: 20240368183Abstract: The present disclose includes, among other things, compounds of formula (I) that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.Type: ApplicationFiled: March 26, 2024Publication date: November 7, 2024Applicant: iTeos Belgium SAInventors: Michael Deligny, Erica Joke Katelijne Heleen Houthuys, Eric Talbot, Mustafa Moroglu
-
Patent number: 11912721Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: GrantFiled: November 24, 2020Date of Patent: February 27, 2024Assignees: UCB Biopharma SRL, SanofiInventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Publication number: 20230407352Abstract: The present disclosure relates to synthesis of enantiomerically rich key drug intermediates as a means for manufacturing of thiocarbamate derivatives as A2A adenosine receptor (A2AR) inhibitors. More particularly, the present disclosure provides a viable efficient technology using enzymatic biotransformation process which utilizes cheaper substrate for production of high value key intermediates for A2AR inhibitors.Type: ApplicationFiled: October 29, 2021Publication date: December 21, 2023Applicant: iTeos Belgium SAInventors: Xuecheng Jiao, Michael Deligny, Stefano Crosignani, Xiangjun Jiang
-
Publication number: 20230203058Abstract: The present invention relates to macrocyclic diamine derivatives of formula II, including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the macrocyclic diamine derivatives with an adenosine receptor antagonist, for the treatment of cancers.Type: ApplicationFiled: April 7, 2021Publication date: June 29, 2023Inventors: Michael Deligny, Stefano Crosginani, Erica Joke Katelijne Houthuys
-
Publication number: 20230146675Abstract: The present invention relates to pyrimido[5,4-d]pyrimidine derivatives of formula I, including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the pyrimido[5,4-d]pyrimidine derivatives with an adenosine receptor antagonist, for the treatment of cancers.Type: ApplicationFiled: August 25, 2022Publication date: May 11, 2023Inventors: Michael Deligny, Stefano Crosginani, Erica Joke Katelijne Houthuys
-
Publication number: 20210155637Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: ApplicationFiled: November 24, 2020Publication date: May 27, 2021Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Patent number: 10906919Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: GrantFiled: December 14, 2018Date of Patent: February 2, 2021Assignees: UCB Biopharma SRL, SanofiInventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Publication number: 20190367535Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: ApplicationFiled: December 14, 2018Publication date: December 5, 2019Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Patent number: 10202405Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: GrantFiled: October 2, 2015Date of Patent: February 12, 2019Assignee: UCB Biopharma SPRLInventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Patent number: 10087179Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: October 2, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Gareth Neil Brace, Julien Alistair Brown, Mark Daniel Calmiano, Prafulkumar Tulshibhai Chovatia, Michael Deligny, Ellen Olivia Gallimore, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Malcolm MacCoss, Joanna Rachel Quincey, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
-
Patent number: 9932343Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: April 3, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
-
Patent number: 9890174Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: February 13, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
-
Publication number: 20170305932Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: ApplicationFiled: October 2, 2015Publication date: October 26, 2017Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Publication number: 20160304523Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: ApplicationFiled: December 8, 2014Publication date: October 20, 2016Inventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
-
Publication number: 20160304530Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogues thereof, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: ApplicationFiled: December 8, 2014Publication date: October 20, 2016Inventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
-
Patent number: 8637496Abstract: The invention relates to the use of compounds having a monogalactosyldiacylglycerol (MGDG) synthase inhibitory activity as herbicide or algaecide, and to herbicide and algaecide compositions containing at least one of these compounds.Type: GrantFiled: June 2, 2008Date of Patent: January 28, 2014Assignees: Commissariat a l'Energie Atomique, Centre National de la Recherche ScientifiqueInventors: Anne-Laure Bonneau, Cyrille Botte, Michael Deligny, Nadia Saidani, Hélène Hardre, Bernard Rousseau, Roman Lopez, Eric Marechal
-
Publication number: 20100292214Abstract: The Invention relates to compounds having an antiparasitic activity, and to their use as a drug, in particular as a drug for the prevention and/or treatment of parasitic diseases caused by apicomplexans. The invention also relates to pharmaceutical compositions containing those compounds.Type: ApplicationFiled: June 2, 2008Publication date: November 18, 2010Applicants: commissariat a l'Energie Atomique, Centre National De La Recherche ScientifiqueInventors: Michael Deligny, Nadia Saidani, Anne-Laure Bonneau, Cyrille Botte, Helene Hardre, Bernard Rousseau, Henri Vial, Corinne Mercier, Roman Lopez, Eric Marechal
-
Publication number: 20100273653Abstract: The invention relates to the use of compounds having a monogalactosyldiacylglycerol (MGDG) synthase inhibitory activity as herbicide or algaecide, and to herbicide and algaecide compositions containing at least one of these compounds.Type: ApplicationFiled: June 2, 2008Publication date: October 28, 2010Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Anne-Laure Bonneau, Cyrille Botte, Michael Deligny, Nadia Saidani, Helene Hardre, Bernard Rousseau, Roman Lopez, Eric Marechal